SIM
AVTX icon

Spark Investment Management’s Avalo Therapeutics AVTX Stock Holding History

Spark Investment Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4
Closed -$28K – 54
2020
Q3 		$28K Hold
4
– – 0.04% 47
2020
Q2 		$32K Hold
4
– – 0.12% 68
2020
Q1 		$31K Sell
4
-5
-56% -$52.9K 0.02% 332
2019
Q4 		$140K Sell
9
-14
-61% -$148K 0.02% 486
2019
Q3 		$216K Sell
23
-8
-26% -$89.3K 0.03% 328
2019
Q2 		$482K Buy
31
+2
+7% +$30.3K 0.03% 375
2019
Q1 		$484K Buy
29
+11
+61% +$165K 0.02% 410
2018
Q4 		$167K Sell
18
-5
-22% -$55.7K 0.01% 519
2018
Q3 		$302K Hold
23
– – 0.02% 515
2018
Q2 		$288K Buy
+23
New +$274K 0.02% 509

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Spark Investment Management's AVTX Position: Q4 2020 in Review

Spark Investment Management sold out of Avalo Therapeutics (AVTX) in Q4 2020, closing a stake of 4 shares — an estimated $28K sold.

Spark Investment Management first reported a position in AVTX in Q2 2018 and held it in 10 quarters. The position peaked at $484K in Q1 2019. 53 funds tracked by Wall St. Rank hold AVTX as of Q4 2020.

  • Spark Investment Management reported no remaining Avalo Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Spark Investment Management sold 4 Avalo Therapeutics shares in Q4 2020, an estimated $28K.
  • Spark Investment Management first reported a position in Avalo Therapeutics in Q2 2018 and held it in 10 quarters.
  • Spark Investment Management's Avalo Therapeutics position peaked at $484K in Q1 2019.
  • 53 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2020.

Based on Spark Investment Management's 13F filing for Q4 2020, filed 11 Feb 2021.